The Federal Circuit affirmed a Patent Trial and Appeal Board (“Board”) decision to uphold the unpatentability of several claims of a patent owned by Affinity Labs of Texas, LLC (“Affinity”). An Examiner initially found the claims to be unpatentable during two inter partes reexaminations and an ex parte reexamination of Affinity’s patent. Apple and [...]
The story in question was written by Sam Biddle and published on April 21, 2015. The article quoted heavily from Lynton's emails, which became public thanks to a massive intrusion that the Obama administration attributed to the North Koreans in advance of the release of the Seth Rogen film The Interview. When the hack [...]
On Monday, April 5th, The New York Times reported that Tesla had surpassed Dearborn, MI-based automaker Ford Motor Company (NYSE:F) in terms of market capitalization, pushing past Ford’s $45.6 billion market cap to hit a $51.2 billion market cap. The following day, shares of Tesla passed $300 per share after having gained 20 percent over the past few months alone. As [...]
The event titled Promoting Innovation, Investment and Job Growth by Fixing America’s Patent System was well attended by a who’s-who of power players within the IP community. The focus of the program was to explore the direct and essential role that strong and enforceable patents play in allowing investors and entrepreneurs to engage in [...]
On Thursday, April 27th, legal data analytics firm Lex Machina released a Hatch-Waxman/ANDA litigation report detailing trends and key findings from pharmaceutical cases filed in U.S. district courts between January 1st, 2009, and March 31st, 2017. More than eight years worth of data shows that patent infringement case filings in response to abbreviated new drug applications (ANDAs) filed [...]
On April 6, 2001, before the critical date, Helsinn entered into two agreements with MGI Pharma, Inc., including a Supply and Purchase Agreement. The agreements were announced via press release, which included redacted copies (price and specific dosage formulations were omitted). The Supply and Purchase Agreement included a provision conditioning performance on favorable clinical [...]
